Pharmaron, Inc.

Pharmaron, Inc. Phamaron Inc. Division, a minority-owned, Subcontinent Asian American-owned contract research organization based in Waltham, Massachusetts, delivers preclinical drug development services to federal agencies as a prime contractor on 96% of recent awards, competing predominantly in full-and-open procurements without set-aside designations. The vendor specializes in pharmacokinetic studies, toxicity assessments, ion channel testing, and absorption-distribution-metabolism-excretion (ADME) evaluation across rodent and primate models, performing work at domestic divisions (Louisville, Kentucky; Rockville, Maryland) and an international division in China.

Pharmaron's customer base concentrates sharply on the National Institutes of Health. The top five customer agencies account for 98% of recent awards, dominated by the National Institute on Drug Abuse (35 awards, $21.5 million combined potential value) and the National Center for Advancing Translational Sciences (33 awards, $1.3 million combined potential value). The two rankings diverge markedly — NIDA drives both volume and dollars while NCATS places many smaller purchase orders — reflecting NIDA's larger funding envelope for preclinical toxicology and metabolic-disorder studies. Representative prime work includes a $124.2 million sole-source purchase order from NCATS for pharmacokinetic evaluation of dystonia compounds in mice, dogs, and rats (September 2023); a $117.4 million firm fixed-price purchase order from NIDA for evaluation of NNMT inhibitors in metabolic disorders (August 2022, Louisville, Kentucky); a $78.3 million NCATS purchase order for cardiac ion channel testing (December 2022, Louisville); and recent 2026 purchase orders from NCATS for single-dose pharmacokinetic studies of RXFP1-agonists ($19.3 thousand, Rockville, Maryland) and mouse PK/PD studies of NNMT inhibitors ($50.3 thousand, Rockville). The vendor sits on the NIH Bioanalysis Testing Services parent vehicle, which generated 27 task orders valued at $925 thousand. Category concentration reflects the preclinical-services profile: 55 awards fall under Testing Laboratories and Services NAICS, with 62 awards classified under Reference Laboratory Testing PSC.

Activity has moderated in recent years — nine awards in 2023 declining to five in 2024 and two in 2025 — with only $70 thousand in combined potential value reaching ultimate completion inside the next twenty-four months, limiting near-term recompete pressure. Pharmaron operates as a sub-recipient on federal grants, collaborating with Sanford Burnham Prebys Medical Discovery Institute on three NIH-funded sub-awards (May 2024, October 2024, October 2025) to deliver chemistry manufacturing and controls (CMC), DMPK, safety assessment, and regulatory data formatting work supporting preclinical candidate nomination and Investigational New Drug submissions. Service Contract Inventory captures minimal activity — six sub-reported records with 8.1 FTEs in FY2022, declining to near-zero in FY2024–FY2025 — reflecting that Pharmaron's federal revenue streams flow primarily through small purchase orders and grants rather than SCI-reportable service contracts above the $150,000 threshold. The vendor competes full-and-open across all major awards without SBA set-asides.